+1 (202) 780-3397
Mini Review - Journal Clinical Psychiatry and Cognitive Psychology (2024) Volume 8, Issue 4
Neuroplasticity and Cognitive Therapy: Implications for Psychotic Disorders.
Article type: Mini Review
Home Page URL: https://www.alliedacademies.org/journal-clinical-psychiatry-cognitive-psychology/
Journal short name: Cogn. Psychol
Volume: 8
Issue: 4
PDF No: 201
Citation: Tanaka Y. Neuroplasticity and Cognitive Therapy: Implications for Psychotic Disorders. Cogn Psychol. 2024; 8(4):201
*Correspondence to: Yuki Tanaka *, Head of Cognitive Rehabilitation Research, University of Tokyo, Japan. Email: yuki.tanaka@tokyo-u.ac.jp
Received: 27-Jul-2024, Manuscript No. AACPCP-24-159096; Editor assigned: 01-Aug-2024, PreQC No. AACPCP-24-159096 (PQ); Reviewed: 15- Aug-2024, QC No. AACPCP-24-159096; Revised: 22- Aug -2024, Manuscript No. AACPCP-24-159096 (R); Published: 29- Aug -2024, DOI:10.35841/AACPCP-8.4.201
Yuki Tanaka *
Head of Cognitive Rehabilitation Research, University of Tokyo, Japan
Introduction
Neuroplasticity, the brain's ability to reorganize and form new neural connections in response to experience and learning, is a groundbreaking concept with profound implications for mental health treatment. This dynamic process, once thought to be limited to early childhood, continues throughout adulthood and plays a critical role in recovery from mental health disorders, including psychotic disorders like schizophrenia. When combined with cognitive therapy, the concept of neuroplasticity opens new avenues for enhancing treatment outcomes, offering hope for patients struggling with the debilitating symptoms of psychosis.
Understanding psychotic disorders and cognitive challenges
Psychotic disorders, particularly schizophrenia, are characterized by symptoms such as hallucinations, delusions, disorganized thinking, and impaired insight into one’s condition. These symptoms can significantly impact cognitive functions, such as attention, memory, executive function, and processing speed, making daily life difficult for those affected. Traditional treatments, including antipsychotic medications, primarily focus on managing the positive symptoms (e.g., delusions and hallucinations), but they are less effective in addressing the cognitive and negative symptoms, which can contribute to long-term disability.
Cognitive therapy, particularly Cognitive Behavioral Therapy (CBT), has shown promise in addressing the cognitive distortions and maladaptive thinking patterns associated with psychotic disorders. However, the addition of neuroplasticity-focused interventions represents a novel and more comprehensive approach, targeting both the brain’s neural pathways and the cognitive processes that sustain psychotic symptoms.
Neuroplasticity and psychotic disorders
Neuroplasticity offers hope for individuals with psychotic disorders by suggesting that the brain can adapt and compensate for damage or dysfunction caused by illness. Research has shown that certain areas of the brain, such as the prefrontal cortex, which is responsible for higher cognitive functions like decision-making, attention, and impulse control, often show reduced activity in individuals with psychosis. This dysfunction is believed to contribute to the cognitive deficits and disorganized thinking observed in these patients.
By promoting neuroplasticity, it is possible to encourage the reorganization of neural circuits and strengthen the connections within these brain regions. This can potentially restore cognitive function and alleviate some of the cognitive and negative symptoms associated with psychotic disorders. Cognitive therapy, particularly when paired with neuroplasticity-based interventions, can facilitate these changes by engaging patients in tasks and exercises that stimulate brain activity and cognitive processing.
Conclusion
The integration of neuroplasticity into cognitive therapy presents a groundbreaking approach to treating psychotic disorders. By promoting the brain's ability to reorganize and strengthen neural pathways, this combined approach offers hope for improving cognitive function, reducing negative symptoms, and enhancing overall psychiatric outcomes. As research into neuroplasticity continues to grow, it is likely that these interventions will become increasingly central to the treatment of psychosis, offering individuals with these challenging conditions a better chance for recovery and improved quality of life.
References
Stephenson S. Vibrant: A Groundbreaking Program to Get Energized, Own Your Health, and Glow. BenBella Books; 2021.
Rehman R, Sheikh A, editors. Polycystic Ovary Syndrome-E-Book: Basic Science to Clinical Advances Across the Lifespan. Elsevier Health Sciences; 2022.
Ford-Martin P, Baker J. The Everything Guide to Managing Type 2 Diabetes: From Diagnosis to Diet, All You Need to Live a Healthy, Active Life with Type 2 Diabetes-Find Out What Type 2 Diabetes Is, Recognize the Signs and Symptoms, Learn How to Change Your Diet and Discover the Latest Treatments. Simon and Schuster; 2012.
Wright H. The PCOS diet plan: A natural approach to health for women with polycystic ovary syndrome. Ten Speed Press; 2017 May 2.
Calonje JE, Brenn T, Lazar AJ, et al. McKee's Pathology of the Skin, 2 Volume Set E-Book. Elsevier Health Sciences; 2018.
Evans M, Wilkinson M, Giannpolou A. Fast-acting insulin aspart: the rationale for a new mealtime insulin. Diabetes Therapy. 2019;10:1793-800.
Indexed at, Google Scholar, Cross Ref
Giorgino F, Battelino T, Bergenstal RM, et al. The Role of Ultra-Rapid-Acting Insulin Analogs in Diabetes: An Expert Consensus. Journal of Diabetes Science and Technology. 2023:19322968231204584.
Indexed at, Google Scholar, Cross Ref
Hoogwerf BJ, Pantalone KM, Basina M, et al. Results of a 24-week trial of technosphere insulin versus insulin aspart in type 2 diabetes. Endocr Pract. 2021;27(1):38-43.
Indexed at, Google Scholar, Cross Ref
Glastras SJ, Cohen N, Dover T, et al. The clinical role of insulin degludec/insulin aspart in type 2 diabetes: an empirical perspective from experience in Australia. J. Clin. Med.ine. 2020;9(4):1091.
Indexed at, Google Scholar, Cross Ref
Shah VN, Al?Karadsheh A, Barnes C, et al. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of NovoLog in adults with type 1 diabetes: The GEMELLI X trial. Diabetes Obes. 2023.